Two large observational studies published last year in the Journal of the American College of Cardiology (JACC) are raising questions about the need for β-blockers in all patients after a first heart attack. Both found a limited mortality benefit associated with use of β-blockers in certain clinical scenarios, underscoring the need for randomized clinical trials (RCTs) designed to test the effectiveness of these historical drugs in the contemporary era, the researchers said.
Abbasi J. Do All Patients Need β-Blockers After a Heart Attack?. JAMA. 2018;319(9):853–855. doi:10.1001/jama.2018.0107
Customize your JAMA Network experience by selecting one or more topics from the list below.